Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RCHP-S is a novel pectin polysaccharide isolated and purified from Rubus chingii Hu, a plant traditionally used as a healthy food in China. Structurally, it is composed of mannose, rhamnose, glucuronic acid, galacturonic acid, glucose, galactose, and arabinose, primarily featuring HG-type pectin domains with a minor presence of RG-I. This polysaccharide has demonstrated anti-inflammatory effects by significantly inhibiting the mRNA expression and secretion of key inflammatory mediators, including inducible nitric oxide synthase (iNOS), interleukin-1 beta (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α) in macrophage cells. In preclinical studies, RCHP-S effectively reduced symptoms of dextran sulfate sodium (DSS)-induced colitis in mice, suggesting its potential as a food additive for treating intestinal inflammation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on RCHP-S.